drugset
drugset / Trial / NCT02722278

A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

NCT02722278 ↗

Phase 3 Completed 222 enrolled Clarus Therapeutics, Inc. Syneos Health · collab
RandomizedParallel-groupOpen-labelBasic science

Summary

A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Timeline

Start
2016-03
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Testosterone Small molecule 60 mg Topical
Subject Testosterone Undecanoate Small molecule 237 mg Oral

Indications

hypogonadism, male